Insider Sale by Chief Business Officer

Timothy P. Moran, Chief Business Officer of Kestra Medical Technologies Ltd (NASDAQ:KMTS), disposed of a total of $348,310 worth of common shares across three separate transactions in late July and early August 2026. The first transaction on July 30 involved the sale of 4,117 shares at a weighted‑average price of $22.7735 per share. The second transaction on July 31 comprised 8,759 shares sold at a weighted‑average price of $22.6054 per share. The final transaction on August 3 consisted of 2,380 shares sold at a weighted‑average price of $23.7611 per share. All sales were nondiscretionary and executed to satisfy tax‑withholding obligations arising from the vesting and settlement of restricted stock units.

Post‑Sale Ownership

Following the three sales, Mr. Moran directly beneficially owns 66,345 common shares of Kestra Medical Technologies.

Stock Performance Context

At the time of reporting, Kestra Medical’s shares were trading at $28.02, representing a rise from the $22‑$24 range at which the insider sales occurred. The stock is near its 52‑week high of $30.00 and has delivered a 75% total return over the past year, according to InvestingPro data. The platform’s analysis notes that the current price appears overvalued relative to its fair‑value estimate and that subscribers have access to ten additional ProTips.

Recent Quarterly Results

Kestra Medical Technologies reported a significant increase in revenue for its fiscal fourth quarter of 2026, with revenue rising 66% year‑over‑year to $28.64 million. Despite the revenue growth, the company posted a loss of $0.67 per share, which was wider than Wall Street’s consensus expectation of a $0.58 per‑share loss.

Analyst Coverage and Ratings

Stifel reiterated its Buy rating on Kestra Medical and maintained a price target of $30.00 following the earnings release. Wolfe Research also raised its price target to $30.00, citing strong execution that exceeded its internal models. JPMorgan initiated coverage with an Overweight rating, highlighting the potential of the company’s ASSURE wearable cardioverter defibrillator. Oppenheimer initiated coverage with a Perform rating, noting the large addressable market and increased market share against incumbent competitors.

---